GLP-1 supply and new capacity plans

What happened

On 21 September 2026, Novo Nordisk held a Capital Markets Day in London, an event where a company sets out its strategy for investors. Its release lists ambitions through 2030, including scaling capacity so it can serve 10 times more people with obesity on an oral GLP-1 (a GLP-1 medication taken by mouth instead of by injection), and serving more than 60 million patients worldwide. These are targets Novo Nordisk set for itself, not capacity it has already built.

The same day, Eli Lilly broke ground on a 6.5-billion-US-dollar plant in Houston, Texas. The plant will make active pharmaceutical ingredient (the substance that gives a medicine its effect, made before it goes into a tablet or pen) for medicines including Foundayo (orforglipron), which Lilly calls its first synthetic oral GLP-1 medicine. Lilly expects the site to employ more than 600 people. Its release doesn’t give a date for when the plant will start producing. Quartz reported on 22 September 2026 that the facility is expected to be operational by 2030.

Lilly says Foundayo is approved in the United States and under regulatory review in more than 40 countries, with a full global rollout targeted for 2027. It also says that because Foundayo is a small molecule rather than a peptide, it can be made with more established technology that is more readily scalable. These are Lilly’s statements, and its release doesn’t mention Canada.

What it means in Canada

Manufacturing capacity is the upstream limit on how much medicine a company can make. More of it could give a company more product to supply across the markets it sells in, but it doesn’t decide which countries get that product or when. That depends on decisions neither release covers: which products are authorized in Canada, whether a company chooses to sell here, and how it divides what it makes between countries. We haven’t checked Foundayo’s status with Health Canada for this article.

Novo Nordisk Canada published its own statement three days before the London event. The release, datelined Mississauga, Ontario, 18 September 2026, says the company is confirming an established supply of Ozempic across Canada. It describes the context as increased demand for semaglutide and limited supply of generic options, and says more than one million Canadians use semaglutide. That is the company’s own account, and we haven’t tested it against pharmacy stock.

Health Canada’s Drug Product Database, which we read on 3 October 2026, shows two generic semaglutide injection products as marketed: Dr. Reddy’s Semaglutide Injection (status dated 6 May 2026) and Apotex’s Apo-Semaglutide Injection (14 May 2026). It shows four more as approved but not yet marketed: Apotex’s Sevmia, two Aspen Pharmacare Canada products and Sandoz Semaglutide, the latest with a status date of 16 September 2026. The database records approval and marketing status, not how much product is on shelves, so we can’t compare it with Novo Nordisk Canada’s “limited” description. Our generics page tracks each product, and what Ozempic costs in Canada explains how a pharmacy sets its price.

What hasn’t changed

Neither announcement puts new medicine on a Canadian pharmacy shelf. Lilly’s plant has only just broken ground, and Novo Nordisk’s capacity figure is an ambition, not built capacity. Pharmacy prices and drug plan rules haven’t changed either. Both are set province by province and pharmacy by pharmacy, and our coverage pages and price pages track them with dates.

If you take a GLP-1 medication and have questions about your own supply, your pharmacist and prescriber are the people to ask. You can also compare telehealth providers, which assess you and prescribe but don’t set the price of the medication.

What happens next

Lilly’s Houston plant is at the groundbreaking stage. Quartz reports it is expected to be operational by 2030, and Lilly’s own release says the full global rollout of Foundayo is targeted for 2027. Novo Nordisk’s capacity and patient-reach figures are ambitions within its strategy through 2030. Neither company gave a Canadian date in the releases we read.

We will add a dated update here if Health Canada, Novo Nordisk Canada or Lilly publishes Canadian supply or authorization information. In the meantime, our generics page shows each generic semaglutide product’s status as Health Canada records it. We also cover orforglipron in our report on its heart-safety trial.